Computationally guided high-throughput design of self-assembling drug nanoparticles.
Source check: Needs source check. Not independent scientific confirmation.
Finding: Machine learning integrated with high-throughput experiments identified 100 self-assembling drug nanoparticles from 2.1 million drug/excipient pairings. Two formulations were further characterized ex vivo and in vivo; the reviewed abstract does not establish clinical benefit.
Technology: Random-forest co-aggregation classifier
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- The abstract confirms machine learning integrated with high-throughput experimentation; model architecture and precise selection operation were not assessable from the reviewed material.
- Test and result
- The primary abstract reports 100 self-assembling formulations identified from a search space of 2.1 million drug/excipient pairings (788 drugs, 2,686 excipients). Sorafenib–glycyrrhizin and terbinafine–taurocholic acid received further ex-vivo/in-vivo characterization. Actual physical-screen denominator, sample sizes and controls were not assessed.
- Limitation / still unknown
- Only publisher abstract and metadata were reviewed; article Methods and supplement were inaccessible through PMC due CAPTCHA. Model architecture, screen controls, sample sizes and detailed ex-vivo/in-vivo outcomes were not assessed.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8197729/ · https://doi.org/10.1038/s41565-021-00870-y
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 18 Nov 2026. Review scope: Indexed primary PubMed metadata and author-institution abstract; complete Nature/PMC Methods and supplement not accessible..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.